(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol

CAS: 142217-77-4

Ref. 3D-NA32025

Product Information

• Name: (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol
• Synonyms: Entecavir Intermediate IV, (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cydopentanol, Entecavir intermediate N4, (1S,2S,3S,5S)-5-(2-amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-((4-methylbenzyloxy)methyl)cyclopentanol, Ent-4, Intermediate of Entecavir 2, (1S,2S,3S,5S)-5-(2-amino-6-(benzyloxyl)-9H-purin-9yl)-3-(benzyloxymethyl)cyclopentanol, (1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl) cyclopentanol

Description

(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol is a synthetic compound that is used to treat patients with chronic myeloid leukemia. It has been shown to inhibit tyrosine kinase and interacts with the guanine binding site of the purine nucleoside phosphorylase. This drug also inhibits the enzyme (deoxy)ribonucleotide reductase and competes with adenosine for binding to adenosine receptors. The stereoisomers of this drug are active against chronic myeloid leukemia cells. The S enantiomer is more potent than the R enantiomer and exhibits greater selectivity for leukemic cells than healthy cells. It has also been shown to inhibit nitric oxide synthase and may have anti-

• Brand: Biosynth

Chemical properties

• Molecular weight: 551.64 g/mol
• Formula: C₃₂H₃₃N₅O₄
• Purity: Min. 95%
• Color/Form: White Powder